News & Events about Instil Bio Inc.
Globe Newswire
2 months ago
Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 DALLAS, March 31, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Instil) (NASDAQ: TIL), a clinical-stage ...
Globe Newswire
5 months ago
Phase 1 trial of ITIL-306 in NSCLC, ovarian, and RCC re-opened to enrollment after voluntary pause Initial data readout for ITIL-306 expected in 2023 With recent reprioritization of clinical programs and corporate restructuring, company expects cash runway into 2025, excluding potential financing or...
Globe Newswire
5 months ago
NEW YORK, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Instil Bio, Inc. (Instil Bio or the Company) (NASDAQ: TIL) on behalf of Instil Bio stockholders. Our investigation concerns whether ...
Market News Video
5 months ago
In trading on Wednesday, biotechnology shares were relative leaders, up on the day by about 0.4%. Leading the group were shares of Instil Bio, up about 19.7% and shares of Relmada Therapeutics up about 17.4% on the day...
Globe Newswire
5 months ago
NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against PROG Holdings, Inc. (NYSE: PRG), Fox Corporation (NASDAQ: FOX, FOXA), Instil Bio, Inc. (NASDAQ: TIL), and Twist Bioscience Corp (...